Loading
A phase 3 trial testing KC1036 in oesophageal cancer, now recruiting.
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Oesophageal Cancer is a phase 3 interventional study registered as NCT06194734, led by Beijing Konruns Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma. Planned enrolment is 490 participants (estimated). The study started in 2024-02-05 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.
Shares Beijing Konruns Pharmaceutical, KC1036, Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.